ere’s what we’re looking out for this week in the worlds of pharma and biotech:
Still waiting on that fantastic FDA pick
This may yet be the week that President Trump unveils the new FDA commissioner. If you trust the pollsters, former FDA deputy commissioner Dr. Scott Gottlieb is emerging as the biopharma community’s top choice. Whoever Trump’s so-called fantastic pick is, we can bet that he or she will veer in the direction of deregulation.